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ABSTRACT 12 
 13 
Purpose Lidocaine hydrochloride (LidH) was formulated in sodium carboxymethyl cellulose/ 14 
gelatine (NaCMC/GEL) hydrogel and a ‘poke and patch’ microneedle delivery method was used 15 
to enhance permeation flux of LidH. 16 
 17 
Methods The microparticles were formed by electrostatic interactions between NaCMC and GEL 18 
macromolecules within a water/oil emulsion in paraffin oil and the covalent crosslinking was by 19 
glutaraldehyde. The GEL to NaCMC mass ratio was varied between 1.6 and 2.7. The LidH 20 
encapsulation yield was 1.2 to 7% w/w. LidH NaCMC/GEL was assessed for encapsulation 21 
efficiency, zeta potential, mean particle size and morphology. Subsequent in vitro skin 22 
permeation studies were performed via passive diffusion and microneedle assisted permeation 23 
of LidH NaCMC/GEL to determine the maximum permeation rate through full thickness skin.  24 
 25 
Results LidH 2.4% w/w NaCMC/GEL 1:1.6 and 1:2.3 respectively, possessed optimum zeta 26 
potential. LidH 2.4% w/w NaCMC/GEL 1:2.3 and 1:2.7 demonstrate higher pseudoplastic 27 
behaviour. Encapsulation efficiency (14.9-17.2%) was similar for LidH 2.4% w/w NaCMC/GEL 28 
1:1.6-1:2.3. Microneedle assisted permeation flux was optimum for LidH 2.4% w/w NaCMC/GEL 29 
1:2.3 at 6.1 μg/ml/h.  30 
 31 
Conclusion LidH 2.4% w/w LidH NaCMC/GEL 1:2.3 crossed the minimum therapeutic drug 32 
threshold with microneedle skin permeation in less than 70 min. 33 
 34 
Keywords lidocaine, sodium carboxymethylcellulose, gelatine, hydrogel, microneedles, in vitro 35 
skin permeation  36 
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INTRODUCTION 37 
The delivery of local anaesthesia to lacerated skin regions remains a major challenge for 38 
injectable and ointment drugs (1). For example, the subcutaneous injection delivery of local 39 
anaesthetics, specifically lidocaine hydrochloride (LidH), is clinically reported to cause a burning 40 
type feeling when infused directly into the skin. Also, LidH requires additional active drug 41 
molecules in an ointment formulation to compete with injectable LidH (1-3). A bolus dosage of 42 
LidH by injection is suitable for short duration of action (1-4). However, the treatment of multiple 43 
lacerations in skin may need co-drugs such as epineprine to aid longer time for LidH action, 44 
which may be ineffective due to a shorter sustained subcutaneous infiltration or simply a second 45 
bolus injection after the first lag time (4-6). Lidocaine’s characteristic amide functional group (7) 46 
and its weak base molecule (pKa 7.7) with a lipophilic function while permeating through 47 
biological membranes is still a highly attributable choice of local anaesthesia since its first 48 
chemical synthesis  in 1943 (7,8). Similarly, the protonated LidH is a weakly acidic, hydrophilic 49 
molecule which is easily soluble in water at ambient temperature. Injectable LidH solution in 50 
either the basic or acidic form shares the same local anaesthetic mechanism for the antagonism 51 
of nerve signals in cells by inhibiting the influx of sodium ions through the sodium channels of 52 
biological cell membranes resulting in a response to temporary pain blockage on the skin surface 53 
(9-11). LidH is dependent on a drug vehicle as a support material with respect to viscoelastic 54 
bulking and balancing of the encapsulation efficiency with enhanced skin permeation 55 
pharmacokinetics. Sodium carboxymethylcellulose (NaCMC) polymer and gelatine (GEL) co-56 
polymer, according to a defined mass ratio are suitable candidates in mapping the crosslinking 57 
structure with the functional role of trapping LidH and with the goal for optimised skin permeation 58 
pharmacokinetics (12). 59 
 60 
 61 
 62 
Sodium carboxymethylcellulose and gelatine (NaCMC/GEL) microparticulates form covalent 63 
linkages between NaCMC’s hydroxyl group lactonisation with the aldehyde of glutaraldehyde’s -64 
CHO group in the formation of ether bonds under low pH conditions (12) (Fig. 1a). A schiff base 65 
association between glutaraldehyde and gelatine is formed by covalent linkage in minimising 66 
ionic dissociation between NaCMC with GEL in neutral media (12,13) (Fig 1a). Also, ionic 67 
interactions occur between polyanionic NaCMC, glycine and proline amino acids of a 68 
polycationic GEL and cationic LidH with the effect of charge neutralisation (14,15) (Fig 1b). 69 
Overall, this process forms a pH sensitive hydrogel network of NaCMC intertwined with GEL 70 
crosslinks for trapping active molecules such as LidH (16,17). The most ideal pH for 71 
electrostatically crosslinking NaCMC with GEL is at pH 4.0 from the view point of zeta potential 72 
analysis. The LidH NaCMC/GEL vehicles are hydrogel microparticles because of pH sensitivity 73 
across a factor of 3.5 which interrupts the electrostatic interactions, allowing the release of 74 
trapped drug molecules (18). In the context of electro-ionic interactions concerning the 75 
formulation, there is no significant quantitative study on ionic interactions between NaCMC, GEL 76 
and LidH with respect to potentiometric measurements, pH thresholds and polarography analysis. 77 
These are fairly important parameters for relating ionic properties but zeta potential analysis 78 
looks into the dispersion of microparticles in the hydrogel as a result of the degree in like charge 79 
Fig. 1a 
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repulsion which is discussed later. The microparticles in LidH NaCMC/GEL hydrogel alone 80 
cannot optimise skin permeation kinetics and a minimally invasive skin puncturing device is 81 
essential in aiding the optimisation of skin permeation kinetics. Recent advances in microneedle 82 
technology promises to resolve this issue and allow microneedle assisted LidH delivery from 83 
NaCMC/GEL hydrogel. 84 
 85 
 86 
Microneedles are minimally invasive micron scale needles protruding perpendicularly from a 87 
laterally mounted platform. It is a painless method of micro-injection for not hitting pain receptors 88 
concentrated in the dermal layer of skin (19). The planar surface and geometrical properties of 89 
the microneedles, and the texture of skin, which is relatively impermeable to large aqueous, 90 
active molecules and drug molecules in a bulk polymeric formulation, can increase permeation 91 
through the viable epidermal layer of skin via micro channel cavities created by microneedles 92 
(20,21). Biomedical grade stainless steel is a suitable metallic alloy for microneedles as it allows 93 
for fast and economical shape cutting to specific dimensions in-conjunction to retaining its highly 94 
desirable compressive strength properties (21,22). For example, we find that Type 304 stainless 95 
steel has been chosen to prepare microneedles in some studies because of its biocompatibility 96 
and inherently good compressive and shear force properties (23). 97 
 98 
Recent advances in lidocaine delivery methods involved liquid crystalline polymeric microneedle 99 
arrays which successfully delivered 71% of LidH by mass using a coat and poke method with a 100 
therapeutic level maintained for approximately five minutes (24). Solid microneedles were also 101 
structured from solution components of lidocaine, mixed with sodium chondroitin sulfate and 102 
cellulose acetate as water soluble vehicles (25). Skin permeation analysis sustained a 103 
therapeutic threshold of lidocaine between 89-131 μg/g for an approximate duration of two and a 104 
half minutes before crossing the maximum therapeutic level pertaining toxicity greater than 105 
131μg/g for over ten minutes (25). A detailed review explaining the current material properties, 106 
fabrication process and pharmacokinetic delivery of LidH in polymeric microneedles are 107 
discussed in detail by Nayak and Das (26). 108 
 109 
The development of LidH NaCMC/GEL hydrogel coupled with microneedle delivery via a poke 110 
and patch method is a promising approach (26). The approach requires no additional active co-111 
drugs when formulated with NaCMC/GEL polymeric mass ratios as the most abundant drug 112 
vehicle reagents. Co-drugs for LidH significantly add to the cost of the final product than NaCMC 113 
and GEL vehicles in abundance. However, at the moment, there is little known about the 114 
significance of microneedle assisted permeation of LidH from the micro-particles in NaCMC/GEL 115 
hydrogel, and in particular, the relationship of the permeation kinetics with the geometrical 116 
parameters of microneedles, e.g., the length of the microneedles. In addressing these issues, 117 
this work aims to develop a LidH formulation in NaCMC/GEL hydrogel and, explore, for the first 118 
time, a poke and patch microneedle delivery method for the purpose of improved drug 119 
permeation rates and permeation flux of LidH. The overall goal is towards an optimised 120 
cumulative amount of lidocaine in watery plasma media, enhanced lidocaine permeation flux and 121 
encapsulation efficiency in-conjunction with a sustained therapeutic permeation range 122 
transdermally of over fifteen minutes. As explained in detail previously, LidH, as a weak acid, can 123 
Fig. 1b 
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be bound electrostatically within soluble drug vehicles consisting of crosslinked NaCMC and GEL 124 
macromolecules. NaCMC, GEL and glutaraldehyde are cheap, biocompatible and readily 125 
available compounds as potential drug formulas in constructing a carrier for LidH. LidH 126 
molecules diffuse from the electrostatically formed microparticle to the surrounding deionised (DI) 127 
water, analogous to the watery plasma of the viable epidermis of skin. The operation of the poke 128 
and patch technique allows for LidH from hydrogel to permeate through microneedles formed 129 
holes on the skin and dissolve into the viable epidermis. The microparticles in the LidH 130 
NaCMC/GEL hydrogel are hydrophilic in nature. A concentration gradient between LidH 131 
NaCMC/GEL hydrogel and underlying watery plasma of skin allows for LidH to dissociate from 132 
NaCMC/GEL hydrogel and associate as lidocaine into the neutral watery plasma. Skin 133 
permeating rates will be compared for passive diffusion and microneedle assisted diffusion of 134 
LidH NaCMC/GEL hydrogels. 135 
 136 
MATERIALS AND METHODS 137 
A laboratory scale batch process for the formulation of LidH NaCMC/GEL hydrogel is highly 138 
advantageous with respect to low heat treatment and quite efficient preparation times in reaching 139 
the desired product. The high degree of carboxylate substitution of NaCMC of 0.9 enhances the 140 
possibility of greater crosslinking with type A, i.e., high bloom gelatine. As explained in the 141 
introduction, the crosslinking is electrostatically achievable at pH 4. LidH is a favourable drug 142 
molecule in association with NaCMC/GEL at pH 4 for encapsulation purposes. The 143 
glutaraldehyde is necessary in defining spherical microparticles from water in oil (w/o) droplets. 144 
 145 
Materials 146 
Sodium carboxymethylcellulose (degree of substitution (DS): 0.9; molecular weight (MW): 250 147 
kD), sorbitan monooleate (SPAN 80), glutaraldehyde (stock solution of 50% w/w), paraffin liquid 148 
(density: 0.859 g/ml), LidH (MW: 288.81 g/mol) and porcine gelatine (type A, Bloom 300) were 149 
purchased from Sigma-Aldrich Ltd, Dorset, UK. Acetic acid (analytical grade), acetonitrile (HPLC 150 
grade), ammonium bicarbonate (analytical grade) and n-hexane (95% w/w) were purchased from 151 
Fisher Scientific Ltd, Loughborough, UK. Deionised (DI) water was the common solvent for 152 
aqueous solutions unless otherwise stated. 153 
 154 
Constant encapsulation of drug LidH in hydrogel of different NaCMC/GEL mass ratios 155 
The mass ratio of NaCMC/GEL outlines one of the formulation characteristics in relation to LidH 156 
pharmacokinetics in this study. Therefore, different NaCMC/GEL mass ratio polymers were 157 
encapsulated with a constant LidH dosage. The individual reagents/chemicals chosen for this 158 
purpose are represented in Table i. A non-ionic surfactant, Span 80 (0.5% w/w), was dispersed 159 
dropwise in 100 ml of light paraffin oil, which was stirred at 400 rpm in a rotating vessel (IKA-160 
Werke, Staufen, Germany) until a homogeneous mixture was formed. Aqueous NaCMC (1.2% 161 
w/w) was then dispersed dropwise into the paraffin/surfactant mixture with shear induced at 400 162 
rpm using the same rotating vessel followed by aqueous dropwise dispersion of gel (CGEL,% w/w) 163 
until a viscous w/o emulsion was formed (Table i). The variable mass percentage of the GEL is 164 
denoted by the term CGEL. 165 
 166 
 167 
Table i 
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 168 
In the next step, the pH of the w/o mixture was decreased to pH 4 using acetic acid (~ 1% w/w). 169 
LidH (2.4% w/w) was then dispersed drop wise into the emulsion and cooled in a refrigerator (4-170 
6ºC) for 30 minutes. The cooled LidH NaCMC/GEL emulsion was agitated in a rotating vessel 171 
(IKA-Werke, Staufen, Germany) at 400 rpm to re-suspend the emerging hydrogel microparticles 172 
before the drop wise addition of glutaraldehyde (0.1% w/w). The w/o droplets were transformed 173 
into microparticles by the glutaraldehyde and stirred at 1000 rpm for a duration of 2 hours to 174 
ensure thorough mixing. The resultant LidH NaCMC/GEL formulation was stored at 2-4°C in a 175 
laboratory refrigerator (Liebherr-Great Britain Ltd, Biggleswade, UK) for a period of 4 h to allow 176 
for the separation of residual paraffin liquid (organic layer) from a dense LidH NaCMC/GEL 177 
formulation layer. The organic layer was cloudy in appearance as compared with the lower 178 
dense layer. After refrigeration, the organic layer was syringe removed. The refrigerated LidH 179 
was mixed with an organic solvent, n-hexane (50% v/v) for the subsequent removal of residual 180 
organic solvent. Any remaining residual organic solvent was oven dried under vacuum at 40°C to 181 
enhance solvent evaporation (Technico, Fistreem International Ltd, Loughborough, UK). Finally, 182 
any unbound LidH was removed through filter washing with DI water. The grade 3 filter 183 
(Whatman International Ltd, Oxon, UK) that was used for the formulation washing stagehad an 184 
average pore size of 6 μm. The LidH NaCMC/GEL hydrogels were collected in amber vials and 185 
characterised for passive diffusion and microneedle assisted skin permeation. 186 
 187 
Different encapsulation of drug LidH in hydrogel of constant NaCMC/GEL mass ratio  188 
The plausible effect of varying LidH concentration on constant NaCMC/GEL mass ratios is 189 
necessary in exploring significant changes in pseudoplasticity and microparticle dispersion. In 190 
this case, the preparation methods and conditions were replicated as those adopted for constant 191 
LidH encapsulation experiments described earlier. However, on this occasion, the initial LidH 192 
concentration in the NaCMC/GEL hydrogel was varied in the range 1.2-7.0% w/w prior to 193 
achieving a hydrogel of certain NaCMC/GEL mass ratio. LidH NaCMC/GEL with 1:1.6 and 1:2.3 194 
mass ratios of microparticles were prepared to evaluate visco-elasticity and zeta potential effects 195 
for a variable LidH encapsulated concentration (Table i). 196 
 197 
The Unloaded NaCMC/GEL 1:2.3 mass ratio hydrogel 198 
The effect of pH on zeta potential for unloaded NaCMC/GEL 1:2.3 mass ratio hydrogel was used 199 
as a control in this study to explore the ideal pH conditions for microparticle dispersion. 200 
Unencapsulated GEL to NaCMC mass ratio of 2.3 for hydrogel microparticles, which were  201 
devoid of LidH, were replicated from the same methods and conditions as for the constant LidH 202 
encapsulation to evaluate the zeta potential effects (Table i). 203 
 204 
In vitro permeation of LidH from NaCMC/GEL microparticles 205 
A Franz diffusion cell for vitro skin permeation was used in exploring and understanding the 206 
pharmacokinetics of LidH prepared with different NaCMC/GEL mass ratios. The Franz diffusion 207 
cell is a common method for transdermal permeation studies. It has two compartments which 208 
comprises of a donor (open cylinder lid) and a receptor. The skin sample is sandwiched between 209 
the two compartments (27). The donor compartment represents the interface between the drug 210 
component and skin surface (28). In particular, this research infers the receptor compartment is 211 
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the interface between lower viable epidermis/upper dermis regions of porcine skin with deeper 212 
dermis layer of skin in the water plasma, receptor compartment (28). In this work, microneedle 213 
assisted diffusion of LidH NaCMC/GEL (Fig. 2) were studied using full thickness porcine skin. All 214 
skin samples were excised from an ear auricle with approximate dimensions of 20.0 x 20.0 x 215 
0.73 mm which were acquired from four to five months old piglets and stored at -20.0°C. The 216 
procurement of swine auricles were confirmed to be pre-washed in plain water and purchased in 217 
a non-mutilated condition from swine cadaver. An approximate force of 0.57N per array 218 
perpendicular to the base was directed on AdminPatch microneedles (Nanobiosciences, 219 
Sunnyvale, CA, USA) pre-fabricated from stainless steel with arrow head geometry. The 220 
microneedles were applied on the skin for a total duration of 5 minutes. This corresponds to the 221 
time duration we needed to pierce the skin without bending or damaging the microneedle. We 222 
wanted to ensure that each experiment with microneedle is conducted for a consistent time of 223 
application and thumb force. From our experiments (e.g, staining experiments) we found that it 224 
was necessary to apply the microneedles for about 5 minutes on the skin sample before we 225 
obtained detectable holes on the MN. Many microneedles (e.g., those which are coated with 226 
drugs or biodegradable in nature) are designed to stay in the skin for longer duration (e.g., 30 – 4 227 
hours) so that the drugs loaded on the microneedles are released. This is not the case in this 228 
study and we apply the microneedles for 5 minutes to create the holes on the skin. The force 229 
inducer supporting a flat based punch dye was lowered below the flat microneedle base before 230 
the application of forces was directed on the microneedle array by hand leverage. At the end of 5 231 
minutes the applied force was released, the microneedle array was carefully removed and a 232 
constant mass of LidH formulation (0.10 ± 0.03g) was placed on the skin. This technique is a two 233 
stage process commonly described as “poke and patch” (29) where the “patch” in this context is 234 
the applied hydrogel formulation.  235 
 236 
 237 
 238 
It is known that the penetration depth of the microneedles is less than the actual microneedle 239 
lengths. Further, the penetration depth depends on the microneedle density on the patch, 240 
providing all other factors (e.g., tissue) remaining the same. From the histology of the skin with 241 
and without microneedles, we observe that the lengths of the holes created by the microneedle 242 
are roughly about 50-60% of the actual microneedle length for normal thumb force applied in this 243 
work. 244 
 245 
Passive diffusion studies (Fig. 2) using LidH NaCMC/GEL hydrogel were conducted on the 246 
adjacent section of the same square skin section of precisely the same average dimensions as 247 
previously stated. The same mass of formulation (0.10 ± 0.03g) was placed onto the middle of 248 
the skin to conduct the passive diffusion studies. The Franz diffusion cell set up with a receptor 249 
compartment aperture area of 1.93 ± 0.0005 cm2 was connected to an instrument module in 250 
supporting water circulation and magnetic stirring induction used in measuring the permeation 251 
kinetics of LidH through the skin. The stratum corneum layer in skin was facing the donor lid and 252 
the dermis layer was facing the receptor aperture. The skin surface which is part of the stratum 253 
corneum layer was exposed to a room temperature of 20°C. A stretchable parafilm seal (Fisher 254 
Scientific, Loughborough, UK) placed on the open aperture lid of the donor compartment 255 
Fig. 2 
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prevented air influx to the receptor compartment during syringe removal of DI water. The 256 
receptor compartment which has a volume of 5.3 ± 0.05 ml contained DI water at 37.0°C stirred 257 
at 300 rpm to represent a well-mixed liquid. Unlike most clinical studies concerning physiological 258 
pH mimicked by phosphate buffer solution (30), this work used DI water with respect to 259 
mimicking watery plasma in the lower viable epidermis layer of skin. The use of DI water is 260 
consistent with developmental stage of in vitro skin permeation studies (31). A receptor volume 261 
(1.5 ± 0.05 ml) was syringe removed (Cole-Palmer, Hanwell, UK) at 30 minutes and subsequent 262 
1 hour intervals. This amount was put in a centrifuge vial and centrifuged (1300 rpm) for 6 263 
minutes and the clear supernatant was pipetted out into 2ml vials for HPLC-DA (Agilent 264 
technologies, Wokingham, UK) analysis of LidH concentration. All HPLC analyses were 265 
performed within 24 hours of sample collection from the Franz cell receptor. The results were 266 
obtained in duplicate which were then used to determine average pharmacokinetic variables for 267 
further analysis. The permeation flux was calculated based on two data sets of mass ratio 268 
hydrogel formulations, plotted with error bars representing the random error at 90 % confidence 269 
level. 270 
 271 
In this work, the in vitro permeation of LidH were interpreted by constructing a profile of 272 
cumulative amount of the drug against time as distinct charts in the section for both microneedle 273 
assisted and passive diffusion. A percentage adjustment of 28.0% was calculated from taking the 274 
1.5ml syringe removal volume as the numerator and the 5.3ml receptor compartment volume as 275 
the denominator in obtaining a percentage from a fraction. This percentage adjustment (28.0%) 276 
from the previous dilution was added to the next detected concentration during a lapsed time 277 
period in obtaining a cumulative concentration profile. The cumulative concentration detected 278 
was interpreted into a more tangible parameter of cumulative amount permeated when taking 279 
into account of the receptor compartment’s distinct aperture. The cumulative amount permeated 280 
(Q) was determined by equation (1) (32,33) with coefficient, Cx, the- lidocaine concentration in 281 
receiver compartment at the specific time (h), V - volume of DI water in receptor compartment 282 
(ml) and A - cross sectional diffusion area of receptor aperture (cm2).  283 
 284 Q =  Cx V 
A
                      (1) 285 
 286 
The flux permeation at steady state (Js) was determined by Fick’s first law using equation (2) with 287 
coefficients, Δm/Δt, the amount of drug permeating through the skin per incremental time at 288 
steady state (µg/h) (34,35). 289 
 290 Js =  ΔmAΔt                     (2) 291 
 292 
Analysis of particle size distribution 293 
The particle size distributions in the hydrogel were analysed using laser diffraction particle size 294 
analyser (Series 2000, Malvern Instruments, Malvern, UK). The data were obtained in duplicate 295 
per repeated hydrogel mass ratio sample via superimposition of data points and the particle size 296 
distributions were plotted as particle diameter against percentage particle volume. Particle 297 
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diameters were compared at 10% (d10), 50% (d50) and 90% (d90) regions of total percentage 298 
particle volume. The refractive index of water as the continuous phase medium was adapted in 299 
determining hydrogel microparticle sizes for the particle size analyser.  300 
 301 
Determination of LidH encapsulation efficiency (EE) 302 
The experimentally determined amount of LidH contained in a sample of NaCMC/GEL 303 
microparticles was interpreted in terms of encapsulation efficiency (EE). For the purpose of 304 
determining LidH encapsulation efficiency, a sample weight (5.0%) of LidH GEL/NaCMC 305 
microparticles was measured. DI water representing excess watery plasma (20.0 ml ± 0.1 ml) 306 
was pipetted into the weighed LidH hydrogel sample and heated to 37.0 ± 1°C in a pre-heated 307 
bath (Grant Instruments Ltd, Shepreth, UK). This sample was then sonicated using a commercial 308 
sonifier (Fisher Scientific, Loughborough, UK) at 35W for 10 minutes. It was then filtered using 309 
Nylon 6,6 membranes of 0.1μm pore size (Posidyne membranes, Pall Corporation, Portsmouth, 310 
UK) under gentle vacuum using a Buchner filter setup (Fisher Scientific, Loughborough, UK). 311 
The filtrate was immediately dispensed into a HPLC vial of volume 1.5 ml. The HPLC results 312 
were obtained in triplicate which were then used to determine the mean percentage 313 
encapsulation efficiency by using equation 3 (36,37). 314 
 315 % EE =  �actual 5.0% weight of LidH from polymeric ratio sample (g)5.0% theoretical encapsulation weight of LidH �  × 100                                      (3) 
 316 
Zeta potential analysis 317 
The measurement of zeta potential provides a valid indication for microparticle dispersion with 318 
respect to charged particle repulsion between microparticles, and as such, the zeta potential of 319 
the microparticles was measured in this study. Ideal zeta potential thresholds will be discussed in 320 
detail later. The zeta potential of LidH-loaded microparticles was measured using a zetasizer 321 
(Malvern 3000 HAS, Malvern, Malvern, UK). The microparticles in the developed LidH 322 
NaCMC/GEL hydrogel (2.0 ± 0.5 g/ml) diluted in DI water were injected into the sample port, 323 
temperature maintained at 20.0°C and the results were obtained in duplicate. Unloaded 324 
NaCMC/GEL 1:2.3 mass ratio hydrogels without any LidH were also subject to zeta potential 325 
analysis. Likewise, the temperature was maintained at 20.0°C and the results were obtained in 326 
duplicate. 327 
 328 
Measurement of viscosity 329 
The viscoelastic property of the variable LidH NaCMC/GEL hydrogel formulation requires 330 
investigation so as to maintain consistency of the formulation and since the rheological 331 
properties of the hydrogel affects its flow through the holes created by the microneedles. In this 332 
case, we used a rotational viscometer (Haake VT 550, Thermo Fisher Inc, Massachusetts, USA) 333 
for determination of bulk (average) dynamic viscosity of the samples of LidH NaCMC/GEL 334 
hydrogels (maximum volume 25 ml). An NV cup and rotor segment (dimensions of length: 60 335 
mm and radius: 20.1 mm) with a gap of 0.35mm was acquired after a brief qualitative 336 
observation of samples as a thick, semi-solid texture. The shear rate was ramped from 1 s-1 to 337 
200 s-1 and held constant at 200 s-1 for 30 s. The viscosity measurement experiments were 338 
carried out at ambient condition of 20°C. NaCMC/GEL hydrogel is not a thermoresponsive 339 
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polymer, so the effects of viscosity against temperature at different, shear rates were not 340 
considered in the paper. Rheological properties of the hydrogel in this paper represent the 341 
normal condition for storage at ambient temperature and not the body temperature.  342 
 343 
 Optical micrography of microparticles in LidH NaCMC/GEL hydrogel 344 
The microparticles in LidH NaCMC/GEL hydrogel are visible optically and the increasing mass of 345 
Gel in the LidH NaCMC/GEL hydrogel provides a significant trend in microparticle morphology. A 346 
sample volume of ~30 µl containing the microparticles of LidH NaCMC/GEL hydrogel was 347 
pipetted onto a slide placed on the stage of an optical microscope (BX 43, Olympus, Southend-348 
on-Sea, UK) which was used to obtain the micrographs.  349 
 350 
Analysis of LidH concentration using high performance liquid chromatography (HPLC) 351 
LidH concentrations were analysed by using HPLC. The mobile phases in eluting LidH were 352 
acetonitrile (HPLC grade) and 10mM ammonium bicarbonate solution (pH 7.5), respectively, in 353 
an isocratic gradient ratio of 50:50. The flow rate of 0.4 ml/min and column temperature of 354 
20.0°C (Perkin Elmer, Series 1100, Cambridgeshire, UK) was kept constant. LidH molecule was 355 
detected by a diode array detector with the wavelength set at 210 nm (Agilent, Series 1100, 356 
Berkshire, UK). The system’s tube lines were purged after eluent degrassing with helium. The 357 
baseline corrections were performed before the injection of 5μl of LidH standard and a 358 
characteristic peak was identified and recorded. 359 
 360 
Standard solutions of lidocaine hydrochloride were prepared in ultrapure water with 361 
concentrations ranging from 1.0 to 64.0 μg/ml from a stock solution of 1.0 mg/ml. Each standard 362 
solution was analysed by HPLC in duplicate to obtain a linear profile of known concentration 363 
against mean area under curve of the integrated lidocaine peak. The HPLC column 364 
specifications are Gemini-NX 3μm particle size of reverse phase, C18 compound composition 365 
and physical dimensions of 100 x 2 mm, which was purchased from Phenomenex, Cheshire, UK. 366 
The mean area under signal peak corresponding to serial standard concentrations for LidH (0.5- 367 
64.0 ppm) was plotted with a linear regression analysis (R2= 0.999) which showed very good 368 
agreement with the data points.  369 
 370 
RESULTS 371 
Desirable trends and outlines of results are organised with sub-headings concerning LidH 372 
NaCMC/GEL hydrogel formulation and pharmacokinetics of LidH permeation through the skin 373 
with relation to therapeutic levels.  374 
 375 
Encapsulation of LidH in NaCMC/GEL microparticles 376 
The mean percentage of LidH encapsulated in the NaCMC/GEL microparticles as a function of 377 
mass ratio of NaCMC to GEL is plotted in Fig. 3. LidH 2.4% w/w NaCMC/GEL 1:2.7 mass ratio 378 
showed the highest encapsulation efficiency of 32% (standard deviation (SD) = 1.2%) as 379 
compared with the microparticles of lower NaCMC/GEL polymeric ratios.  380 
 381 
 382 
  383 
Fig. 3 
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Viscoelasticity of LidH NaCMC/GEL hydrogel 384 
The results in this work (Fig. 4a) suggest that the increase in LidH concentration had no 385 
significant effect on the average dynamic viscosity of the hydrogel. In particular, the data points 386 
after the shear rate of 100 s-1 outlined a single asymptote and they superimposed well (Fig. 4a). 387 
The minimum dynamic viscosity of constantly encapsulated LidH NaCMC/GEL hydrogels (Fig. 388 
4b) from the shear range 100 to 200 1/s asymptote is found to be 0.14 Pa.s for LidH 389 
NaCMC/GEL 1:2.0 mass ratio, which may provide a low pseudo plasticity to the hydrogel. Within 390 
the shear range 100 to 200 sec-1 asymptotes of 0.28 and 0.31 Pa.s are found for LidH 391 
NaCMC/GEL 1:2.3 and 1:2.7 mass ratios, respectively and they account for little difference in 392 
pseudo plasticity. But a marked difference in pseudo-plasticity is observed when LidH 393 
NaCMC/GEL 1:2.0 mass ratio is compared with LidH NaCMC/GEL 1:2.7 mass ratio (Fig 4b). 394 
Substantially, there is no significant difference in shear thinning dynamic viscosity induced by a 395 
constant maximum shear of 200 s-1 when comparing LidH 2.4% w/w NaCMC/GEL variable mass 396 
ratio hydrogels. This outlines very good reproducibility with SD of 0.02 for each LidH 397 
NaCMC/GEL hydrogel mass ratios (Fig. 5).  398 
 399 
 400 
 401 
Distribution of microparticles in LidH NaCMC/GEL hydrogel  402 
The particle size distribution curves were noticeably similar for LidH 2.4% w/w NaCMC/GEL 403 
1:2.3 and 1:2.7 mass ratios with the same mean particle diameter of 140 µm (Fig. 6) for each 404 
one. As found, the d10 values were 29 μm and 35 μm for LidH NaCMC/GEL 1:2.3 and 1:2.7 mass 405 
ratios, respectively. Also, the the d90 values were 305 μm and 277 μm for LidH NaCMC/GEL 406 
1:2.3 and 1:2.7 mass ratios, respectively (Fig. 6). The particle size distribution was considerably 407 
left skewed, less broad in describing the peak outline for LidH 2.4% w/w NaCMC/GEL 1:1.6 408 
mass ratio with a mean particle diameter of 98.65 µm where d10 = 19.3 µm and d90 = 301.78 μm 409 
were recorded (Fig. 6). 410 
 411 
 412 
 413 
Zeta potential of LidH NaCMC/GEL mass ratio and pH effects in microparticles 414 
In developed microparticles, LidH loading ranges from 1.2-2.8% w/w for NaCMC/GEL 1:1.6 mass 415 
ratio resulted in no significant change in zeta potential (SD = 0.09) and showed excellent 416 
reproducibility in comparison to the high zeta potential values and poor reproducibility of LidH 7.0% 417 
w/w NaCMC/GEL 1:1.6 mass ratio (SD = 1.84) (Fig: 7a). LidH 2.4% wt and 2.8% wt, loaded each 418 
in NaCMC/GEL 1:1.6 and 1:2.3 mass ratios showed good reproducibility (SD = 0.10 and SD = 419 
0.05 respectively) and desirably low zeta potential values approaching -40 mV (Fig. 7b). 420 
 421 
 422 
 423 
LidH 2.4% w/w NaCMC/GEL 1:1.6 till 1:2.3 mass ratios provided desirably low zeta potential 424 
values approaching -40 mV and good reproducibility (SD = 0.76) compared with LidH 425 
NaCMC/GEL 1:2.7 mass ratio in which the zeta potential was undesirably high and, hence, 426 
agglomeration was more significant due to the high gelatine concentration (Fig. 7c). The 427 
Fig. 4a, 4b Fig. 5 
Fig. 6 
Fig. 7a Fig. 7b 
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hydrogel microparticles may have unbound gelatine flocculating and diverting the innermost 428 
negative charge boundaries of defined LidH loaded NaCMC/GEL microparticles. LidH 2.4% and 429 
2.8% w/w encapsulated NaCMC/GEL 1:2.3 mass ratio depict desirable and stable zeta potential 430 
values close to -40 mv despite LidH 2.8% w/w loaded NaCMC/GEL 1:2.3 mass ratio outlining a 431 
slightly lower reproducibility (SD = 0.80) (Fig. 7d). Also LidH 7.0% w/w encapsulated 432 
NaCMC/GEL 1:2.3 mass ratio depicted a repeat of the high zeta potential behaviour in terms of 433 
an undesirably high and slightly more agglomeration effect due to high loading of LidH (Fig. 7d).  434 
 435 
 436 
 437 
The effect of pH on NaCMC/GEL 1:2.3 resulted in f (x) = -2.8x3 + 50.5x2 – 273.1x + 404.4 (Fig. 8) 438 
where f (x) = ζ (mV). A good fit from low standard deviation, error bars represented close 439 
agreement between experimentally determined data and theoretical data (Fig. 8). 440 
 441 
 442 
Morphology of microparticles in LidH NaCMC/GEL hydrogel  443 
The micro-particles of LidH 2.4% w/w NaCMC/GEL 1:1.6 to 1:2.7 mass ratio were found to be 444 
spherical. However they show small areas of agglomeration with respect to microparticulate 445 
hydrogel morphology (Fig. 9a.-9d). The microparticles in LidH 2.4% w/w NaCMC/GEL 1:1.6, 446 
1:2.3 and 1:2.7 mass ratios appear slightly more distinct spherically and dispersed with less 447 
agglomeration compared with LidH 2.4% w/w NaCMC/GEL 1:2.0 mass ratio. More significantly in 448 
the quantity with regards to larger microparticle sizes were observed for LidH 2.4% w/w 449 
NaCMC/GEL 1:2.7 mass ratio hydrogel (Fig. 9d). 450 
 451 
 452 
 453 
Microneedle assisted and passive diffusion of LidH from NaCMC/GEL hydrogel 454 
Clinical research has shown that LidH in plasma fluid is able to sustain localised drug action at a 455 
normal threshold range of 1.2 to 5.5 µg/ml or 3.11 µg/cm2 to 14.25 µg/cm2 after conversion into 456 
cumulative permeated amounts for LidH (47,48). Microneedle assisted diffusion of LidH 457 
NaCMC/GEL 1:2.3 mass ratio showed a fast time taken for the cumulative amount permeated at 458 
1.1 h after crossing the minimum LidH therapeutic level. Comparatively, the same LidH 459 
formulation used for passive diffusion studies showed the fastest time in crossing the minimum 460 
therapeutic level regarding the cumulative amount permeated was 1.5 h (Fig 10a). During the 461 
microneedle assisted diffusion of LidH NaCMC/GEL, 1:1.6 and 1:2.0 mass ratios both outlined 462 
faster times taken for the cumulative amount permeated past 1.25 h when extrapolated towards 463 
a minimum LidH therapeutic level. Comparatively the passive diffusion of LidH NaCMC/GEL 464 
1:1.6 mass ratio and passive diffusion of LidH NaCMC/GEL 1:2.0 mass ratios crossed the 465 
minimum therapeutic level at 2h and 3h, respectively (Fig. 10a). The error bars from duplicate 466 
data sets showed very good reproducibility (Fig 10a). Permeated rates of microneedle assisted 467 
LidH NaCMC/GEL hydrogels recorded in the first 0.5 h, were significantly high for 1:2.3 mass 468 
ratio with a 20.5 fold increase when compared with passive diffusion and low for 1:2.0 mass ratio 469 
with a 1.4 fold increase compared with passive diffusion (Fig. 10b). Likewise as discussed, the 470 
error bars from duplicate data sets showed good reproducibility (Fig 10b). 471 
Fig. 8 
Fig. 9a-d 
Fig. 7c Fig. 7d 
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 472 
 473 
LidH NaCMC/GEL 1:1.6 mass ratio formulation represented the lowest microneedle assisted 474 
permeation flux of 3.8 µg/ cm2/ h (Fig. 10c) despite a low microparticle size diameter of nearly 99 475 
µm compared with other NaCMC/GEL mass ratio formulations. In theory smaller microparticles 476 
should allow greater ease in passing skin pores and diffusing water plasma in the lower regions 477 
of the skin. Nevertheless the zeta potential results with respect to a very low zeta correlating to 478 
greater dispersion than agglomeration of microparticles is the main supporting concept for high 479 
permeation flux. The random error of permeation flux for the duplicate data sets showed good 480 
reproducibility (Fig 10c). 481 
 482 
 483 
 484 
DISCUSSION 485 
 486 
Surfactant and oil based continuous phase medium in emulsion stage preparation 487 
Paraffin oil as the continuous phase mixed with non-ionic surfactant, SPAN 80 (sorbitan 488 
monooleate), for stabilising aqueous emulsion droplets possessed ideal properties (38).  489 
Comparatively SPAN 20, SPAN 40 and SPAN 60 series were unsuitable surfactants because 490 
SPAN 80 is the most hydrophobic and accounts for much slower emulsion phase inversion from 491 
W/O to W/O/W (38). However, a water content in the range of 10 -15% w/w and temperature at 492 
60°C allow for emulsion phase inversions in SPAN 20 and SPAN 80 (38). This phase inversion 493 
phenomenon is highly unlikely to occur as the temperature of the LidH NaCMC/GEL emulsion 494 
was kept below 35°C despite the aqueous phase content was determined above 15% w/w. 495 
Paraffin oil, continuous phase medium aided the dispersion of polar droplets before further 496 
addition of glutaraldehyde for microparticle formation. The n-octonol/water partition coefficient of 497 
paraffin oil is noted, log P >3.5 (Fisher Scientific Ltd, Loughborough, UK) and the non-polarity is 498 
attributed to the high interfacial tension and lower dielectric constant in terms of % w/w 499 
solubilisation (39). The formation of a NaCMC/GEL polymeric hydrogel network is to entrap and 500 
crosslink a linear polymeric structure with a more branched structure in considering covalent 501 
bonding interactions to a lesser extent, thus permitting intermolecular dissociation in a 502 
continuous phase such as water (40,41). Glutaraldehyde was used for fixing and strengthening 503 
the crosslinking of a polymer and co-polymer to form spherically shaped microparticles (42). 504 
 505 
The effect of increasing Gel concentration on encapsulation efficiency of LidH 506 
NaCMC/GEL 507 
Gelatine in greater concentrations in hydrogel NaCMC/GEL microparticles influences the gelling 508 
properties of the hydrogel matrix with respect to crosslinking with NaCMC at low pH via 509 
electrostatic charges and hypothetically creating a more complex intertwined mesh to trap LidH 510 
molecules. In order to gain a better insight into the reason for a substantially valid increase in 511 
encapsulation efficiency from 1:2.3 mass ratio NaCMC/GEL to 1:2.7 mass ratio requires electro-512 
analytical research with respect to overall ionic charge distribution effects. However this is not 513 
within the scope of this current paper. 514 
 515 
Fig. 10a Fig. 10b 
Fig. 10c 
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Visco-elastic and particle diameter properties of LidH NaCMC/GEL hydrogel  516 
LidH is weakly acidic and the positively charged tertiary amide in it has no effect on influencing 517 
the pseudoplasticity of the NaCMC/GEL hydrogel (Fig. 4a). Increasing the GEL ratio 518 
concentration component in the LidH polymeric hydrogel microparticles slightly increases the 519 
pseudoplasticity of the hydrogel formulation caused by gelling thus appearing more pronounced 520 
with respect to LidH NaCMC/GEL 1:2.3 and 1:2.7 mass ratios. This has an influence on creating 521 
bigger microparticle sizes as discussed later in particle size distribution (Fig. 6). Mild 522 
pseudoplasticity is a common viscoelastic property for LidH NaCMC/GEL hydrogels despite low 523 
values pointing to shear thinning at a maximum shear of 200 1/s (Fig. 4a and 5). 524 
 525 
The reduced hydrogel matrix properties caused by a much lower gelatine ratio concentration for 526 
LidH NaCMC/GEL hydrogel despite a constant high  shear of 1000 rpm during the formulation 527 
preparation stages has a significantly profound decrease of mean particle size diameter when 528 
comparing NaCMC/GEL 1:1.6 mass ratio with NaCMC/GEL 1:2.3 and 1:2.7 mass ratios (Fig. 6). 529 
Morphologically larger microparticles in LidH NaCMC/GEL hydrogel are distinctly represented for 530 
the 1:2.7 mass ratio with respect to the highest concentration of GEL co-polymer (Fig. 9). A 531 
similar polymeric GEL microparticle study (43) obtained volume mean particle size range from 532 
247-535μm for 1:4 and 1:9 NaCMC/GEL ratio non-steroidal anti-inflammatory drug (NSAID) 533 
mainly because of low overhead stirring speeds of 400 rpm, high viscosity grade NaCMC (500-534 
800 mPas) and higher co-polymer, gelatine concentration in the ratio mixture.  535 
 536 
Polyelectrostatic LidH NaCMC/GEL and Unloaded NaCMC/GEL microparticles on zeta 537 
potential 538 
A high concentration of weakly acidic LidH in a low polycationic GEL weight ratio NaCMC/GEL 539 
hydrogel formulation is likely to influence slightly more agglomeration of microparticles. Also the 540 
high LidH concentration disrupted the complex coacervate formation before the permanent 541 
fixation and assembly of droplets into defined spherical microparticles by glutaraldehyde (Fig. 7a). 542 
Low agglomeration was already deduced from low zeta potential values and there was no 543 
significant difference for further reduced agglomeration and metastable particle stability when 544 
LidH 2.4% wt or 2.8% w/w is encapsulated in either NaCMC/GEL 1:1.6 or 1:2.3 mass ratios, 545 
respectively (Fig. 7b). However LidH 7.0% w/w loaded in NaCMC/GEL 1:1.6 and 1:2.3 mass 546 
ratios showed significantly higher, positive, zeta potential values and therefore slightly more 547 
agglomeration of microparticles (Fig. 7b). 548 
 549 
The zeta potential effect of charged particles with a charge distribution density on the inner core 550 
provides a good indication of a metastable and non-agglomerated particulate hydrogel in the 551 
empirically determined range of -31.0 to -40.0 mV (44,45). The surface charges in the 552 
microparticles of LidH NaCMC/GEL hydrogel are negative due to dissociation of acidic groups on 553 
GEL and LidH contributing to an acidic environment in forming a spherical core shell structure in 554 
conjunction to electronegative DI water molecules, basic carboxylate groups in NaCMC and 555 
conjugate base of acetic acid contribute to the outermost shell boundary (45,46). Zeta potential is 556 
a fairly common and valid analytical technique for determining the LidH NaCMC/GEL 557 
microparticles in dispersal from weak acid medium of pH 4.0 to a near neutral plasma pH 558 
medium. Placebo NaCMC/GEL hydrogel microparticles outline the minima (dζ/d(pH) = 0) which 559 
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is representative of the lowest zeta value showed the most desirable pH value at -58.6 mV (Fig. 560 
8) so pH 4.0 was the ideal and adapted pH for NaCMC/GEL overall hydrogel media in the 561 
encapsulation of LidH. Above acidic conditions of pH 4.0 for the placebo NaCMC/GEL 1:2.3 562 
mass ratio resulted in a gradual increase in zeta potential which is likely caused by reduction in 563 
dissociated polycationic GEL and polyanionic NaCMC, and microparticle agglomeration is more 564 
defined. 565 
 566 
LidH from NaCMC/GEL hydrogels as a transdermally permeating agent  567 
The minimum therapeutic and toxic level permeation thresholds values were taken from 568 
references (47,48), converted from micrograms per millilitre concentration of LidH into 569 
micrograms per square centimetres for permeated concentration using equation 1 and 570 
expressed using constants derived from Franz diffusion cell receptor compartment volume and 571 
receptor area of aperture in equation (4). 572 
 573 Q = 5c
1.93                      (4) 574 
 575 
Commercially acquired AdminPatch microneedles (Nanobiosciences, Sunnyvale, CA, USA) 576 
created channels and widened skin pores for the drug to bypass the stratum corneum layer and 577 
diffuse into the viable epidermis. Staining techniques have shown similar length AdminPatch 578 
microneedles to penetrate beyond the SC layer of skin from a recent study (31). Imperatively the 579 
use of microneedles is to allow the drug to diffuse just above the minimum therapeutic levels at 580 
lower recorded time durations than passive diffusion which is devoid of any needles. 581 
 582 
The effective diffusional area in considering the barrier diffusing membrane properties of skin 583 
was adapted from Fick’s first law for explaining the permissible trends for passive diffusion and 584 
microneedle assisted cumulative diffusion of LidH NaCMC/GEL hydrogels through the skin. The 585 
LidH 2.4% w/w NaCMC/GEL hydrogels are permeating the uppermost layer, highly lipophilic 586 
layer of skin very slowly for upto 30 minutes (Fig. 10b). After thirty minutes, the permeating 587 
amount of LidH diffuses at a much faster rate because the lower section layer of skin is less 588 
lipophilic and pseudo steady state conditions are observed for all LidH NaCMC/GEL hydrogels 589 
after 1.5 hours (Fig 10a). LidH NaCMC/GEL microparticles enter the opened microneedle treated 590 
skin cavity while for passive diffusion the hair follicles and sweat pores are the natural cavities for 591 
these microparticles (49). The natural cavities in skin are considerably smaller openings when 592 
compared with post microneedle ones (49). Excised skin used in vitro will generally have lower 593 
moisture content because of high trans-epidermal water loss (TEWL) values and microparticles 594 
will tend to cause a reservoir effect in viable or dermis layers of skin (50). After thirty minutes, the 595 
permeating amount of LidH diffuses at a much faster rate because the lower section layer of skin 596 
is less lipophilic and pseudo steady state conditions are observed for all LidH NaCMC/GEL 597 
hydrogels after 1.5 hours (Fig 10a).  598 
 599 
The cumulative skin permeation of the three LidH 2.4% w/w NaCMC/GEL hydrogels depicted 600 
good overall high rates than compared with passive diffusion, especially past the time of 0.5 h 601 
(Fig 10a and 10b).  Emerging plateau levels of cumulative permeation amounts through skin 602 
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were already documented post 4.5 h. However, the aim for a higher LidH amount permeated 603 
past minimum therapeutic levels were particularly targeted at the most plausible shorter time 604 
duration than a long sustained release profile hence comparative cumulative permeation studies 605 
were conducted in a short time range. 606 
 607 
Increasing the gel concentration in a LidH 2.4% w/w NaCMC/GEL hydrogel outlined an increase 608 
in permeation flux for both passive diffusion and microneedle assisted permeation (Fig. 10c). 609 
LidH 2.4% w/w NaCMC/GEL mass ratio 1:2.3 showed a highly favourable permeation flux with 610 
respect to microneedle assisted delivery of LidH. The encapsulation efficiency of LidH 2.4% w/w 611 
NaCMC/GEL mass ratios are similar and therefore cannot explain the effect of increasing LidH 612 
release rates when the Gel mass ratio is increased in the hydrogel vehicle in terms of correlating 613 
with an unchanged encapsulation efficiency just above 15%. However, LidH 2.4% w/w 614 
NaCMC/GEL mass ratio 1:2.7 provided a substantially high encapsulation efficiency of 32% and 615 
a reciprocally poor, highly insignificant, low value skin permeation flux which was interpreted as a 616 
no result. A high gelatine mass weight of 3.3% w/w in LidH 2.4% w/w NaCMC/GEL mass ratio 617 
1:2.7 hydrogel provided for a more compacted gelling and adsorbing properties, thus preventing 618 
the release of a detectable quantity of LidH. The high gelation of LidH 2.4% w/w NaCMC/GEL 619 
mass ratio 1:2.7 microparticles are responsible for agglomeration by high zeta potential (Fig. 7c). 620 
However, LidH 2.4% w/w NaCMC/GEL mass ratio 1:2.3 had a slightly higher and a favourably 621 
closer zeta potential to -40 mV and therefore the permeation flux for passive diffusion and 622 
microneedle assistance is influenced to be highest because of less microparticulate 623 
agglomeration or clustering effect. 624 
 625 
CONCLUSION 626 
LidH NaCMC/GEL is a highly potential and promising hydrogel formulation requiring microneedle 627 
assisted delivery to excel low passive diffusion flux rates by relatively significant proportions. 628 
Microneedle assisted LidH 2.4% w/w NaCMC/GEL mass ratio 1:2.3 hydrogel is found to be the 629 
most ideal formulation for exceeding the minimum therapeutic permeation threshold of 630 
3.11µg/cm2 just after 70 minutes but requiring removal before 140 minutes. A seventy minute 631 
duration for pseudo steady state permeation, concerning LidH 2.4% w/w NaCMC/GEL mass ratio 632 
1:2.3 is highly beneficial in numbing the immediate skin region in a hypothetical case of multiple 633 
lacerations in close proximity that require wound cleaning and suturing.  634 
 635 
LidH 2.4% w/w is the most ideal loading concentration for NaCMC/GEL 1:1.6 and 1:2.3 mass 636 
ratio hydrogel because of reproducible and stable approaching values of -40.0 mV zeta potential. 637 
A buffered pH 4.0 was essential in the induction of an anionic polymer and cationic co-polymer 638 
polyelectrolyte interaction and facilitation of dispersed hydrogel microparticles as measured by a 639 
zeta of -58 mV. There are significant differences in visco-elasticity caused by polymeric ratios of 640 
NaCMC and Gel than the constant loading concentration of LidH when an ideal polymeric mass 641 
ratio 1:2.3 is implemented.  642 
 643 
The envisaged aim for LidH NaCMC/GEL as an ideal painless, local anaesthetic formulation 644 
remains in the early developmental stage due to further challenges in reduction of residual 645 
paraffin oil content, scope for smaller micron scale particle sizes and subsequently higher 646 
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encapsulation efficiency which is the focus of further particle technology investment than 647 
advanced pharmaceutics.  648 
 649 
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Table i. Chemical reagents used for preparing different LidH NaCMC/GEL hydrogel microparticles 
 
Drug Formulation 
 
LidH 
(% w/w) 
 
SPAN 80 
(% w/w) 
 
Paraffin oil 
(% w/w) 
 
Deionised water 
(% w/w) 
 
GEL 
(% w/w) 
 
NaCMC 
(% w/w) 
 
Acetic acid 
(~ % w/w) 
 
Glutaraldehyde 
(% w/w) 
LidH (2.4% w/w) 
NaCMC/GEL 
hydrogel 
microparticles 
 
2.4 
 
0.5 66.7 
26.1 2.0 
1.2 1.0 0.1 
25.6 2.5 
25.3 2.8 
24.9 3.2 
LidH NaCMC/GEL 
1:1.6 mass ratio 
hydrogel 
microparticles 
1.2 
0.5 66.7 
27.3 
2.0 1.2 1.0 0.1 
2.4 26.1 
2.8 25.8 
7.0 21.5 
LidH NaCMC/GEL 
1:2.3 mass ratio 
hydrogel 
microparticles 
1.2 
      0.5       66.7 
26.5  
 
2.8 
 
 
1.2 
 
 
1.0 
 
 
0.1 
2.4 25.3 
2.8 25.1 
7.0 20.7 
Unloaded 
NaCMC/GEL 1:2.3 
mass ratio hydrogel 
microparticles 
 
 
0 
0.5 66.7 27.7 2.8 1.2 1.0 0.1 
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Fig. 1 a Crosslinking between sodium carboxymethyl cellulose (NaCMC) and gelatine A (GEL) via   
ether bonds between NaCMC and glutaraldehyde and schiff’s base C=N linkage between 
glutaraldehyde and proline of GEL. R1, R2, R3 are repeating monomeric units of each polymer. b Ionic 
interactions between NaCMC, proline of GEL and LidH. R1, R2, R3 are repeating monomeric units of 
each polymer. 
 
Fig. 2 Pathways for microneedle assisted and passive diffusion studies of LidH NaCMC/GEL on 
porcine skin via franz diffusion cells. Porcine skin was treated with microneedles before the addition of 
LidH NaCMC/GEL [A] for FDC. The direct addition [B] of LidH NaCMC/GEL is the start of the passive 
diffusion pathway. Sample LidH NaCMC/GEL [C] added to skin undergoes FDC experimentation for 
both microneedle and passive diffusion delivery. The FDC receptor amount was removed and 
centrifuged [D]. The supernatant removed was then analysed using HPLC-DA [E]. Inset is a stainless 
steel microneedle array with a length to width needle aspect ratio of 1:4 and a tip to tip needle spacing 
of 1100 μm. 
 
Fig. 3 Percentage encapsulation efficiency of LidH in hydrogel particles as a function of NaCMC:GEL 
mass ratio. The concentration of lidH in the initial emulsion was 2.4% w/w (Results represent 
arithmetic mean ± SD values based on data from three reproduced hydrogel samples per mass ratio).  
 
Fig. 4 a Dynamic viscosity of LidH NaCMC/GEL 1:2.3 hydrogels as a function of shear rate. b 
Dynamic viscosity of LidH 2.4% w/w in NaCMC/GEL hydrogels as a function of shear rate (Results 
represent data points from individual hydrogel samples per mass ratio).  
 
Fig 5. Constant shear induction (200 s-1) for lidocaine 2.4% w/w NaCMC/GEL hydrogel as a function of 
mass ratio of NaCMC to GEL (Results represent arithmetic mean ± SD values based on data from two 
reproduced hydrogel samples per mass ratio). 
 
Fig 6. LidH 2.4 % (w/w) NaCMC/GEL particle size distribution as a function of mass ratio of the two 
polymer (Results represent superimposed data points of each repeated hydrogel sample from a total 
of six individual hydrogel samples). 
 
Fig. 7 a Zeta potential of LidH NaCMC/GEL 1:1.6 mass ratio microparticles. Values 1.2-7.0 are LidH 
loaded yields in % w/w. b Zeta potential of LidH (2.4-7.0% w/w) NaCMC/GEL mass ratio 1:1.6 and 
1:2.3 microparticles. Values 2.4-7.0 are LidH loaded yields in % w/w. c Zeta potential of LidH (2.4% 
w/w) NaCMC/GEL mass ratio microparticles. d Zeta potential of LidH NaCMC/GEL mass ratio 1:2.3 
microparticles. Values 2.4-7.0 are LidH loaded yields in % w/w (results represent arithmetic mean ± 
SD values based on data from two reproduced hydrogel samples per mass ratio or concentration) 
 
Fig. 8. pH effects on unencapsulated NaCMC/GEL 1:2.3 microparticles as a function of zeta potential. 
Experimental zeta (mV)         Theoretical zeta (mV)      (results represent arithmetic mean ± SD values 
based on data from two hydrogel samples per mass ratio). 
 
Fig. 9. Micrograph of LidH 2.4 % w/w NaCMC/GEL microparticles prepared using different polymeric 
ratios: a) 1:1.6 b) 1:2.0 c) 1:2.3 d) 1:2.7. 
 
Fig. 10 a Cumulative amount of LidH permeated through skin from NaCMC/GEL within a four hour 
period. b Cumulative amount of LidH permeated through skin from NaCMC/GEL within a one hour 
period. c LidH (2.4 % w/w) NaCMC/GEL flux permeation through skin (results in (a) and (b) represent 
arithmetic mean ± SD values based on data from two reproduced hydrogel samples per mass ratio. 
Result in (c) represents random error of two reproduced mass ratio samples for passive diffusion and 
microneedle values based on 90 % confidence level). 
 
 
 
  
 
 
 
 
Fig. 1 a Crosslinking between sodium carboxymethyl cellulose (NaCMC) and gelatine A (GEL) via   
ether bonds between NaCMC and glutaraldehyde and schiff’s base C=N linkage between 
glutaraldehyde and proline of GEL. R1, R2, R3 are repeating monomeric units of each polymer. b Ionic 
interactions between NaCMC, proline of GEL and LidH. R1, R2, R3 are repeating monomeric units of 
each polymer. 
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Fig. 2 Pathways for microneedle assisted and passive diffusion studies of LidH NaCMC/GEL on 
porcine skin via franz diffusion cells. Porcine skin was treated with microneedles before the addition of 
LidH NaCMC/GEL [A] for FDC. The direct addition [B] of LidH NaCMC/GEL is the start of the passive 
diffusion pathway. Sample LidH NaCMC/GEL [C] added to skin undergoes FDC experimentation for 
both microneedle and passive diffusion delivery. The FDC receptor amount was removed and 
centrifuged [D]. The supernatant removed was then analysed using HPLC-DA [E]. Inset is a stainless 
steel microneedle array with a length to width needle aspect ratio of 1:4 and a tip to tip needle spacing 
of 1100 μm. 
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 Fig. 3 Percentage encapsulation efficiency of LidH in hydrogel particles as a function of NaCMC:GEL    
mass ratio. The concentration of lidH in the initial emulsion was 2.4% w/w (Results represent 
arithmetic mean ± SD values based on data from three reproduced hydrogel samples per mass ratio). 
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Fig. 4 a Dynamic viscosity of LidH NaCMC/GEL 1:2.3 hydrogels as a function of shear rate. 
b Dynamic viscosity of LidH 2.4% w/w in NaCMC/GEL hydrogels as a function of shear rate 
(Results represent data points from individual hydrogel samples per mass ratio).  
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 Fig. 5 Constant shear induction (200 s-1) for lidocaine 2.4% w/w NaCMC/GEL hydrogel as a function of 
mass ratio of NaCMC to GEL (Results represent arithmetic mean ± SD values based on data from two 
reproduced hydrogel samples per mass ratio).  
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 Fig. 6 LidH 2.4 % (w/w) NaCMC/GEL particle size distribution as a function of mass ratio of the two 
polymer (Results represent superimposed data points of each repeated hydrogel sample from a total 
of six individual hydrogel samples). 
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Fig. 7 a Zeta potential of LidH NaCMC/GEL 1:1.6 mass ratio microparticles. Values 1.2-7.0 are LidH 
loaded yields in % w/w. b Zeta potential of LidH (2.4-7.0% w/w) NaCMC/GEL mass ratio 1:1.6 and 
1:2.3 microparticles. Values 2.4-7.0 are LidH loaded yields in % w/w. c Zeta potential of LidH (2.4% 
w/w) NaCMC/GEL mass ratio microparticles. d Zeta potential of LidH NaCMC/GEL mass ratio 1:2.3 
microparticles. Values 2.4-7.0 are LidH loaded yields in % w/w (results represent arithmetic mean ± 
SD values based on data from two reproduced hydrogel samples per mass ratio or concentration) 
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 Fig 8  pH effects on unencapsulated NaCMC/GEL 1:2.3 microparticles as a function of zeta potential. 
Experimental zeta (mV)      Theoretical zeta (mV)  
(results represent arithmetic mean ± SD values based on data from two hydrogel samples per mass 
ratio). 
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Fig. 9 Micrograph of LidH 2.4 % w/w NaCMC/GEL microparticles prepared using different polymeric 
ratios: a) 1:1.6 b) 1:2.0 c) 1:2.3 d) 1:2.7. 
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Fig. 10 a Cumulative amount of LidH permeated through skin from NaCMC/GEL within a four hour 
period. b Cumulative amount of LidH permeated through skin from NaCMC/GEL within a one hour 
period. c LidH (2.4 % w/w) NaCMC/GEL flux permeation through skin (results in (a) and (b) represent 
arithmetic mean ± SD values based on data from two reproduced hydrogel samples per mass ratio. 
Result in (c) represents random error of two reproduced mass ratio samples for passive diffusion and 
microneedle values based on 90 % confidence level). 
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